English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Jayson GC et al. remarked in  Lancet  that nearly 100% of mucinous ovarian cancer cases have  Kras  mutation as well as a high frequency of  Her2  amplification. Using the Abbott PathVysion  Her2  DNA Probe Kit and  Kras  mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of  Her2  amplification and  Kras  mutations. Our results showed the  Her2  amplification rates were 33.33%, while the  Kras  mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100%  Kras  mutant frequency and the high  Her2  amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel  Kras  mutations (A11V, V14I).

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma